Skip to Content

Defencath FDA Approval Status

FDA Approved: No
Brand name: Defencath
Generic name: taurolidine
Company: CorMedix Inc.
Treatment for: Prevention of Catheter Related Blood Stream Infections (CRBSI)

Defencath (taurolidine) is a synthetic broad-spectrum antimicrobial and antifungal in development for use as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI).

Development Timeline for Defencath

DateArticle
Nov 18, 2020CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New Drug Application for Defencath is Not Needed
Aug 31, 2020CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath
Jul  8, 2020CorMedix Inc. Reports Submission of Defencathâ„¢ New Drug Application

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.